We are a unique partnership of senior advisors with proven expertise in the translation of precision medicine and health tools into clinical practice and patient impact.
Leadership
Prof. Richard Barker, BSc, MA, DPhil (Oxon), FRSM, HFBPS, OBE
Founder & CEO

Richard Barker is a senior leader in the global life sciences sector with the focus on precision medicine
30-year career in senior executive roles: former Director General of ABPI, Visiting Professor at Oxford University, KCL Chairman of the Health
Innovation Network (NHS) and the Alliance board for the South London Genomic Medicine Centre Speaker, and workshop leader on the precision medicine and longevity.
Dr Olga Shvarova, BSc (Hons), MSc, DPhil (Oxon), RTTP
Non-Executive Director

Olga Shvarova is a Technology Transfer / Commercialisation Expert and Investment Jury Member with European Commission, and has held a number of senior posts in med-tech, M&A, corporate finance and private equity firms. Olga has worked with the health insurance, medical device, and pharmaceutical sectors and acted as a Chief Innovation Officer for an EU-funded Centre of Excellence focussed on emerging digital technologies.
GLOBAL ADVISORY BOARD
Dr Andrew Krentz, BSc, MSc, MD, PhD
Clinical & Pharmaceutical Medicine

Andrew Krentz is an internationally recognised cardiometabolic clinician and researcher. He is President of Vascular Lipid & Metabolic Medicine at the RSM and an elected member of several professional associations including the Royal College of Physicians of London, the Faculty of Pharmaceutical Medicine, the Royal College of Pathologists and the Royal Society of Arts. He is a founding mentor for the Collaboration for the Advancement of Sustainable Medical Innovation (CASMI) at UCL.
Dr Charles Alessi, LRCP, MRCS
Public Healthcare Systems

Charles Alessi has a global presence as chief clinical officer of editohealth and founder of the Radical Health Festival. He has extensive experience dealing with governments, technology, and policy makers at the highest levels. Previous notable
positions include Medical Director for the British Armed forces in Europe, Chief Clinical Officer at H.I.M.M.S and Senior advisor at Public Health England.
Tina Woods, BA, MBA
Healthy Ageing & Data Access

Tina Woods is an author and entrepreneur working in both private and public sectors to accelerate innovation and transform health with sustainable impact at scale. Her current positions include: a CEO and Founder of a health innovation catalyst, Collider Health, a CEO & Founder of a social enterprise aimed at young scientists, Collider Science and a CEO and Co-founder of Longevity International, which works with the secretariat for the All-Party Parliamentary Group for Longevity. Tina also works with national AHSN AI Network to support an AI and data-driven tech ecosystem for the NHS and the new NHSX team on a number of activities including the NHSX AI Lab and with the Healthy Ageing Industrial Strategy Challenge Fund with UK Research & Innovation.
Dr Robert Hariri, AB, MD, PhD
Cell Therapy & Tissue Engineering

Bob Hariri is a surgeon, biomedical scientist and highly successful serial US entrepreneur in two technology sectors: biomedicine and aerospace. He has pioneered the use of stem cells to treat a range of life-threatening diseases and has made transformative contributions in the field of tissue engineering. His current positions include: the Chairman, Founder, and CSO of Celgene Cellular Therapeutics, Academic Neurosurgeon at Cornell, a Non-executive Director of Myos Corporation and Provista Diagnostics, an Adjunct Associate Professor of Pathology at the Mount Sinai School of Medicine, a member of the Board of Visitors of the Columbia University School of Engineering & Applied Sciences and the Science & Technology Council of the College of Physicians and Surgeons, and of the scientific advisory board for the Archon X PRIZE for Genomics.
Dr Alan Roth, BA, MA, MPhil, PhD
Drug Design

Alan Roth is an experienced leader in health sciences integrating basic research, investment management/capital markets, strategic consultancy and executive operations. His career includes New Lead Discovery at Merck & Co., McKinsey, Commerzbank Asset Management ($140bn AUM) and co-founding CEO of the biotechnology company Chiral Quest in chiral pharmaceuticals. He is currently the CEO of Oxford Drug Design, an Oxford University spinout in precision oncology therapeutics led by pioneering AI. Alan is a Royal Society Entrepreneur in Residence and Visiting Lecturer at the University of Oxford, Director at Fitzroy Partners, a Guest Professor at the University of Cologne, the University of Tianjin, and the US Military Academy, West Point.
Prashant Lele, BSc, MSc
Digital Healthcare

Prashant Lele is a seasoned technology executive with extensive experience in digital health innovation and global business development. His expertise spans across AI-driven healthcare solutions including SaaS product integration within public health infrastructure and strategic digital transformation in the life sciences sector in the UK and APAC. He is an advisor to digital health startups, guiding technology strategy and fundraising efforts. Prashant's unique blend of technological acumen and healthcare industry knowledge positions him as a valuable asset in navigating the complex landscape of digital health innovation and global market expansion.
Kasia Zajkowska, MPhil, MSc
Longevity Clinics

Kasia Zajkowska is a bioscientist and entrepreneur specialising in the commercialisation of new technologies and business development in the biotechnology and healthcare sectors with a strong focus on longevity clinics development and operations. With over 20 years of industry experience in researching, developing and bringing scientific advances to the clinic environment, Kasia remains at the forefront of wellbeing innovation, regenerative technologies research and works towards influencing healthcare trends. A University of Cambridge graduate and holding an MPhil in Bioscience Enterprise and MSc in Molecular Biotechnology, Kasia is a current Ph.D. candidate at ISM Paris.